加速与优化CAR-T细胞制造以提供更优患者产品
本综述探讨了自体外嵌合抗原受体(CAR)T细胞治疗中制造工艺的局限与改进策略,重点分析短制造流程、减少扩增方案、无激活方案及即时检验制造等进展,强调快速周转与维持较未分化表型的关系,并讨论简化质量控制以充分实现临床潜力。
要点
- 短制造流程可更快将产品送达患者,并避免长时间体外制造相关的髙分化与耗竭CAR-T表型。
- 自2020年以来,领域转向减少扩增方案、无激活方案和即时检验制造,兼顾快速周转与较未分化表型。
- 上述努力正推动超快速生产方法乃至通过体内制造方法消除体外操作。
核心结论
- 加速CAR-T制造(包括近患者方法)需在提高疗效、缩短周转时间与简化质量控制方面取得进展,以充分实现CAR-T治疗的临床潜力。
研究设计与样本
- 综述类文章,检索范围未在原文中具体报告。
主要发现
- 自体外起始物料与生产工艺质量可严重影响临床结局,改进产品表型的策略至关重要。
- 短制造流程可更快将产品送达患者,并避免长时间体外制造相关的髙分化与耗竭CAR-T表型。
- 历史上策略依赖调整培养基组成与选择较未分化细胞亚型。
- 自2020年以来,领域转向减少扩增方案、无激活方案和即时检验制造,兼顾快速周转与较未分化、耗竭表型。
- 上述努力正推动超快速生产方法乃至通过体内制造方法消除体外操作。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autologous chimeric antigen receptor (CAR) T-cell therapy has transformed the management of B-cell leukaemia and lymphoma. However, current manufacturing processes present logistical hurdles, restricting broader application. As clinical outcomes can be heavily influenced by the quality of autologous starting materials and production processes, strategies to improve product phenotype are crucial. Short manufacturing processes have the advantage of bringing products to patients more quickly and, in parallel, avoiding the highly differentiated and exhausted CAR T-cell phenotypes associated with prolonged ex vivo manufacture. This Review examines advances in our understanding of what constitutes an effective CAR T-cell product and approaches to improve product quality. Historically, strategies have relied on adjustments in medium composition and selection of less differentiated cell subtypes. Since 2020, the field has been shifting towards reduced-expansion protocols, no-activation protocols, and point-of-care manufacturing. These approaches have the advantage of a rapid turnaround while maintaining a less differentiated and exhausted phenotype. These efforts are leading to ultrarapid production methods and even elimination of ex vivo manipulation with the use of in vivo manufacturing approaches. In this Review, we focus on the advances needed to accelerate CAR T-cell manufacture (including near-patient methods), with an emphasis on improved therapeutic efficacy and rapid turnaround time, and simplified quality control procedures required to fully realise the clinical potential of CAR T-cell therapies.
引用
- Agliardi G, Dias J, Rampotas A, et al. Accelerating and optimising CAR T-cell manufacture to deliver better patient products. Lancet Haematol. 2024. PMID: 39510106. doi:10.1016/S2352-3026(24)00273-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。